Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

Studies show XIFAXAN 550 mg tablets demonstrate significant relief of global IBS symptoms

Salix Pharmaceuticals, Ltd. today announced the New England Journal of Medicine has published results from TARGET 1 and TARGET 2, the Company's two pivotal Phase 3 efficacy and safety studies of XIFAXAN (rifaximin) 550 mg tablets for the treatment of Irritable Bowel Syndrome without constipation, or Non-C IBS.

6 Jan 2011

Columbia research team identifies bacteria may play a key role in atherosclerosis

Dr. Emil Kozarov and a team of researchers at the Columbia University College of Dental Medicine have identified specific bacteria that may have a key role in vascular pathogenesis, specifically atherosclerosis, or what is commonly referred to as "hardening of the arteries" - the number one cause of death in the United States.

6 Jan 2011

Bacteria adopt defence strategy to promote antibiotic resistance

Genetic resistance to antibiotics is not the only trick bacteria use to resist eradication- they also have a second defence strategy known as persistence that can kick in.

6 Jan 2011

Water Street Healthcare announces acquisition of OraPharma from Johnson & Johnson

Water Street Healthcare Partners announced today that it has acquired OraPharma, Inc. from Johnson & Johnson. Water Street, a strategic private equity firm focused exclusively on health care, plans to build OraPharma into a leading specialty pharmaceutical company focused on dental and oral health care.

6 Jan 2011

Study: Antibiotics can provide long-lasting relief to patients with irritable bowel syndrome

A ground-breaking antibiotic therapy developed at Cedars-Sinai Medical Center is the first potential drug treatment to provide irritable bowel syndrome patients with long-lasting relief of their symptoms even after they stop taking the medication, according to a study published in the Jan. 6 issue of the New England Journal of Medicine.

6 Jan 2011

EUSA receives FDA Priority Review status for ERWINAZE BLA

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that its Biologics License Application for ERWINAZE(R) has been accepted for filing and awarded Priority Review status by the U.S. Food and Drug Administration.

5 Jan 2011

AMRI, Genentech enter research and licensing collaboration

AMRI announced today a research and licensing agreement with Genentech, a member of the Roche Group, for a family of antibacterial compounds discovered from AMRI's proprietary research of its natural products sample collection.

5 Jan 2011

New program may help reduce hospital readmission rates for high-risk seniors

SCAN Health Plan and Lakewood IPA have partnered with Dovetail Health in a program designed to reduce readmission rates for high-risk seniors following discharge from hospitals and skilled nursing facilities.

4 Jan 2011

The Scientist examines how nonprofit, for-profit pharma groups are working together to make drugs more affordable for developing countries

"With philanthropists funneling billions of dollars into biomedical research and traditional drug discovery efforts producing fewer and fewer therapies, the line between for-profit and nonprofit life science companies is beginning to blur as both sides of the divide look for new options," The Scientist magazine writes in an article that examines the rise in collaborations between nonprofit pharmaceutical companies and for-profit groups.

4 Jan 2011

New guideline provides evidence-based recommendation for children undergoing tonsillectomy

A multidisciplinary clinical practice guideline, "Tonsillectomy in Children" will be published in the January issue of Otolaryngology-Head and Neck Surgery.

3 Jan 2011

Today's opinions: Ariz. hospital and abortion; Wall Street Journal's issues with PolitiFact; Calif.'s anti-smoking success

St. Joseph's Hospital and Medical Center in Phoenix announced on Tuesday that it will continue to provide life-saving abortion care to patients even though it means losing its affiliation with the local Roman Catholic Diocese (12/23).

24 Dec 2010

Over 36,000 people visit interactive infection research exhibition in 2010

The travelling exhibition organised by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) and the Robert Koch Institute (RKI), "Humans and Microbes - Robert Koch's Legacy and Modern Infection Research", has already proved to be a visitor magnet during its very first year. In total, the interactive exhibition attracted more than 36,000 visitors at its three ports of call (Berlin, Bonn and Würzburg), including 400 school classes.

23 Dec 2010

New research sheds light on complex regulatory pathways for effective innate immune system

New research by scientists at the University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences reveals that the immune system has an effective backup plan to protect the body from infection when the "master regulator" of the body's innate immune system fails.

21 Dec 2010

Forest acquires all rights held by Gruenenthal for colistin

The Gruenenthal Group and Forest Laboratories, Inc., today announced that Forest Healthcare B.V., a wholly owned subsidiary of Forest Laboratories, Inc. and Gruenenthal GmbH, have entered into an agreement whereby Forest has acquired all rights currently held by Gruenenthal for colistin and all rights previously licensed by Forest to Gruenenthal for Colobreathe.

20 Dec 2010

NanoLogix enters collaboration with Advanced Medical German Company of Kuwait

NanoLogix, an innovator in the accelerated detection and identification of microorganisms, is pleased to announce its collaboration with Advanced Medical German Company of Kuwait (AMGKWT). This alliance will support NanoLogix's market penetration goals for the Middle East, North and East Africa with the international marketing focus of Advanced Medical German Company stretching from the Middle East through Africa.

20 Dec 2010

Researchers demonstrate that monensin antibiotic prevents prostate cancer cell growth

Researchers from VTT Technical Research Centre of Finland and the University of Turku have demonstrated that an antibiotic called "monensin" prevents the growth of prostate cancer cells. Monensin is used in the meat and dairy industry, for example.

20 Dec 2010

Researchers recommend 'watchful waiting' over antibiotic treatment for many children with ear infections

As middle ear infections increase during the winter months, researchers from Ben-Gurion University of the Negev (BGU) suggest that in many cases the most appropriate treatment is "watchful waiting" instead of using antibiotics immediately.

20 Dec 2010

Accelr8 reports $466,362 net sales revenue for first fiscal quarter ended October 31, 2010

Accelr8 Technology Corporation announced its financial results for the first fiscal quarter ended October 31, 2010. Net sales revenues totaled $466,362; net income from operations was $49,974 with total net income of $67,250. For the previous quarter, net sales were $15,549 with a loss from operations of $(423,373) and a total net loss of $(411,981). Shareholders' equity totaled $4,985,682 at the current quarter's end, up from $4,909,778 at the end of the previous fiscal quarter.

17 Dec 2010

Anacor Pharmaceuticals initiates AN2690 phase 3 program for onychomycosis fungal infection

Anacor Pharmaceuticals announced today that enrollment has been initiated and the first patient has been dosed in the Phase 3 program of AN2690, a topical antifungal product candidate for the treatment of onychomycosis.

16 Dec 2010

Plasma technology safe, effective alternative to antibiotics to treat multi-drug resistant infections

Cold plasma jets could be a safe, effective alternative to antibiotics to treat multi-drug resistant infections, says a study published this week in the January issue of the Journal of Medical Microbiology.

15 Dec 2010

Antibiotic News and Research

Further Reading

Studies show XIFAXAN 550 mg tablets demonstrate significant relief of global IBS symptoms

Columbia research team identifies bacteria may play a key role in atherosclerosis

Bacteria adopt defence strategy to promote antibiotic resistance

Water Street Healthcare announces acquisition of OraPharma from Johnson & Johnson

Study: Antibiotics can provide long-lasting relief to patients with irritable bowel syndrome

EUSA receives FDA Priority Review status for ERWINAZE BLA

AMRI, Genentech enter research and licensing collaboration

New program may help reduce hospital readmission rates for high-risk seniors

The Scientist examines how nonprofit, for-profit pharma groups are working together to make drugs more affordable for developing countries

New guideline provides evidence-based recommendation for children undergoing tonsillectomy

Today's opinions: Ariz. hospital and abortion; Wall Street Journal's issues with PolitiFact; Calif.'s anti-smoking success

Over 36,000 people visit interactive infection research exhibition in 2010

New research sheds light on complex regulatory pathways for effective innate immune system

Forest acquires all rights held by Gruenenthal for colistin

NanoLogix enters collaboration with Advanced Medical German Company of Kuwait

Researchers demonstrate that monensin antibiotic prevents prostate cancer cell growth

Researchers recommend 'watchful waiting' over antibiotic treatment for many children with ear infections

Accelr8 reports $466,362 net sales revenue for first fiscal quarter ended October 31, 2010

Anacor Pharmaceuticals initiates AN2690 phase 3 program for onychomycosis fungal infection

Plasma technology safe, effective alternative to antibiotics to treat multi-drug resistant infections

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News